4D Molecular Therapeutics Newsroom

Morgan Stanley Initiates 4D Molecular Therapeutics(FDMT.US) With Sell Rating, Announces Target Price $8

Moomoo NewsNov 21 05:31 ET

Chardan Capital Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $39

Moomoo NewsNov 14 17:32 ET

4D Molecular Therapeutics Is Maintained at Buy by Chardan Capital

Dow JonesNov 14 16:55 ET

RBC Capital Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating

Moomoo NewsNov 14 07:34 ET

H.C. Wainwright Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $36

Moomoo NewsNov 14 06:31 ET

Promising Pipeline Developments and Expanding Opportunities Lead to Buy Rating for 4D Molecular Therapeutics

TipRanksNov 14 06:19 ET

Barclays Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $45

Moomoo NewsNov 14 05:34 ET

Barclays Reaffirms Their Buy Rating on 4D Molecular Therapeutics (FDMT)

TipRanksNov 14 04:54 ET

4D Molecular Therapeutics Downgraded at Cantor Following Wet AMD Asset Data

Seeking AlphaSep 23 13:42 ET

4D Molecular Therapeutics Analyst Ratings

BenzingaSep 23 12:57 ET

Cantor Fitzgerald Downgrades 4D Molecular Therapeutics(FDMT.US) to Hold Rating

Moomoo NewsSep 23 07:31 ET

A Quick Look at Today's Ratings for 4D Molecular Therapeutics(FDMT.US), With a Forecast Between $36 to $82

Moomoo NewsSep 20 09:00 ET

4D Molecular Therapeutics Is Maintained at Buy by Chardan Capital

Dow JonesSep 19 12:02 ET

A Quick Look at Today's Ratings for 4D Molecular Therapeutics(FDMT.US), With a Forecast Between $36 to $79

Moomoo NewsSep 19 09:00 ET

Analysts Are Bullish on Top Healthcare Stocks: 4D Molecular Therapeutics (FDMT), Satellos Bioscience (MSCLF)

TipRanksSep 19 06:34 ET

RBC Capital Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $40

Moomoo NewsSep 11 07:33 ET

4D Molecular Therapeutics (FDMT) Receives a Buy From RBC Capital

TipRanksSep 11 07:08 ET

The Latest Analyst Ratings For 4D Molecular Therapeutics

BenzingaSep 9 14:02 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: Doximity (DOCS), 4D Molecular Therapeutics (FDMT) and Cullinan Management (CGEM)

TipRanksAug 13 12:23 ET

Buy Rating Affirmed for 4D Molecular Therapeutics Amidst Strong Financials and Promising Pipeline

TipRanksAug 12 18:47 ET